ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >Dabrafenib Mesylate
Dabrafenib Mesylate
- CAS No.
- 1195768-06-9
- Chemical Name:
- Dabrafenib Mesylate
- Synonyms
- Dabrafenib Mesylate;GSK 2118436B;Dapafini mesylate;abrafenibmesylate;Dabrfenib Mesylate;GSK2118436 Mesylate;GSK-2118436 Mesylate;GSK 2118436 Mesylate;Debrafenib Mesylate (API);Dabrafenib Mesylate (API)
- CBNumber:
- CB72630077
- Molecular Formula:
- C24H24F3N5O5S3
- Molecular Weight:
- 615.66
- MOL File:
- 1195768-06-9.mol
- Modify Date:
- 2024/5/24 18:18:52
| Melting point | >234oC (dec.) |
|---|---|
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly, Heated), Methanol (Slightly) |
| form | White solid. |
| color | White to Off-White |
| Stability | Hygroscopic |
| InChIKey | YKGMKSIHIVVYKY-UHFFFAOYSA-N |
| SMILES | S(O)(=O)(=O)C.FC1C(=CC=CC=1C1N=C(C(C)(C)C)SC=1C1C=CN=C(N)N=1)NS(C1C(=CC=CC=1F)F)(=O)=O |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H319-H335-H302+H312+H332-H315 | |||||||||
| Precautionary statements | P301+P312-P302+P352-P305+P351+P338 | |||||||||
| HS Code | 2935909099 | |||||||||
| NFPA 704 |
|
Dabrafenib Mesylate Chemical Properties,Uses,Production
Description
Dabrafenib mesylate, sold by GlaxoSmithKline under the trade name Tafinlar, was approved by the U.S. FDA in May 2013 for the treatment of metastatic BRAF-mutant melanoma. Dabrafenib reversibly inhibits the BRAF(V600E) mutant kinase as a selective ATP-competitive inhibitor which results in tumor regression.
Uses
Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
Definition
ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma.
Dabrafenib Mesylate Preparation Products And Raw materials
Raw materials
2,6-Difluorobenzenesulfonyl chloride
N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide
Dabrafenib
N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide
Methyl 3-(2,6-difluorophenylsulfonamido)-2-fluorobenzoate
chevron_left
1of2
chevron_rightPreparation Products
Global( 190)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Venkatasai Life Sciences | +91-9908134868 +91-8008303069 | Hyderabad, India | 186 | 58 | Inquiry |
| MSN LABORATORIES PRIVATE LTD | +91 40 30438600 | New Delhi, India | 230 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Beijing Mesochem Technology Co.,Ltd | +8613651027935 | China | 191 | 58 | Inquiry |
| Zison Pharmaceutical (Shandong) Co., Ltd. | +86-0086-531-88259693 +86-18660188356 | China | 57 | 58 | Inquiry |
Related articles
- Dabrafenib Mesylate(GSK-2118436B): A Potent Inhibitor in Targeted Cancer Therapy
- Dabrafenib Mesylate, chemically recognized as GSK-2118436B, marks a groundbreaking advancement in oncological therapeutics.
- May 8，2024
- Dabrafenib Mesylate(GSK-2118436B): Pharmacodynamics and Applications in Cancer
- Dabrafenib Mesylate(GSK-2118436B) targets BRAF V600E in cancer, synergizing with trametinib to inhibit the RAS/RAF/MEK/ERK pat....
- Apr 3，2024
- What cancers can Dabrafenib Mesylate treat?
- Dabrafenib mesylate in combination with trametinib dimethyl sulfoxide is used to treat cancer patients with a certain BRAF gen....
- Nov 7，2023
1195768-06-9(Dabrafenib Mesylate)Related Search:
chevron_left
1of2
chevron_right
Dabrafenib Mesylate(GSK-2118436B)
GSK 2118436 Mesylate
GSK 2118436B
GSK2118436 Mesylate
GSK-2118436 Mesylate
Dabrafenib Mesylate (API)
GSK 2118436 methanesulfonate salt
N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide methanesulfonate
N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate
GSK2118436 Ms salt, Dabrafenib Ms salt, GSK2118436A Ms salt
Debrafenib Mesylate (API)
Dabrafenib, Methanesulfonate Salt
Dabrfenib Mesylate
N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzen
Dabrafenib Mesylate (GSK-2118436)
Dapafini mesylate
DABRAFENIB MESYLATE (GSK 2118436B);GSK-2118436 MESYLATE;GSK2118436 MESYLATE;GSK 2118436 MESYLATE
Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)
abrafenibmesylate
Dabrafenib Mesylate (GSK2118436 Mesylate
N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid
Dabrafenib Mesylate
Dalafenib methanesulfonate
1195768-06-9
C23H20F3N5O2S2CH4O3S
C24H24F3N5O5S3
Raf B protein kinase inhibitor
API